AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01721200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
Study NCT01319006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
Study NCT01319006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
Study NCT04191759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test-Retest reproducibility
Description: Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
Study NCT01278446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed, whey protein infant formula
Description: New hydrolyzed formula
Study NCT04425226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
Study NCT04425226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
Study NCT03736525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Design For Wellness (DWELL)
Description: Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
Study NCT03736525 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list control group
Description: Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
Study NCT04090736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
Study NCT04090736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
Study NCT04090736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
Study NCT02753751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKI Alert
Description: Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves.
Study NCT02265705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT02265705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02703844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Vestibular Stimulation
Description: Stimulation of the vestibular nerves
Study NCT02703844 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Caloric Vestibular Stimulation
Description: Sham stimulation of the vestibular nerves
Study NCT01047683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 4 g/day
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
Study NCT01047683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 2 g/day
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
Study NCT01047683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
Study NCT03701477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-diagnostic cognitive-behavioral therapy
Description: 10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
Study NCT03701477 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General relaxation/stress management therapeutic session
Description: Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
Study NCT00614939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 2.5 mg once daily oral dose
Study NCT00614939 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Placebo
Description: Placebo
Study NCT00824109 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Second Generation Anti-Microbial bifurcated vascular graft (InterGard)
Description: treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
Study NCT02379598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Aminoacid based formula
Description: Formula based on aminoacid
Study NCT02379598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Hydrolyzed whey formula
Description: Formula based on hydrolyzed whey protein
Study NCT03650205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine capsule
Study NCT03650205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule.
Study NCT03959501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dapagliflozin 10mg daily for 24 weeks
Study NCT03959501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100mg daily for 24 weeks
Study NCT02806986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20%
Description: Weekly administration of IGSC 20% via intravenous infusion
Study NCT03038373 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
Study NCT06089304 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
Study NCT02063503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: every group receives 2 treatments every week during 9 consecutive weeks
Study NCT00499187 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draws
Description: A single whole blood sample was collected for genomic analysis.
Study NCT03566719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
Study NCT01278446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolyzed, casein protein infant formula
Description: Commercially available hydrolyzed infant formula
Study NCT02292407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure Precise instrument
Description: LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
Study NCT02272972 — intervention group
Intervention type: OTHER
Intervention: Application of knowledge
Description: Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
Study NCT02954432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study NCT02566837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
Study NCT02566837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
Study NCT02464969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablet or Solution
Study NCT02464969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
Study NCT04188535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.
Study NCT02606136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
Study NCT05279261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The axillary approach
Description: The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
Study NCT00466323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Member Provider Outreach
Description: Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
Study NCT00466323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual (e-TAU)
Description: Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
Study NCT02954432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study NCT02954432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT02954432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT01436097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision intervention
Description: Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
Study NCT01436097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: information provision + flat incentive
Description: Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
Study NCT01436097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision + tiered incentive
Description: In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
Study NCT01436097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
Study NCT03139474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin-Releasing Hormone Analogue
Description: Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
Study NCT03139474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin releasing hormone antagonist
Description: antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach > 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
Study NCT00723502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin + Amoxicillin
Description: Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
Study NCT00723502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin + Esomeprazole
Description: Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
Study NCT04535934 — intervention group
Intervention type: OTHER
Intervention: Adenine 5+ (five stable-labeled nitrogens)
Description: taggant coencapsulated with an excipient
Study NCT01603550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Sleep Deprivation
Study NCT01603550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Energy Restriction
Study NCT05915065 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coapt Phantom Limb Pain Management System
Description: The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
Study NCT02188823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Study NCT01775137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBM100
Description: Tobramycin inhalation powder (TIP) 112mg/b.i.d
Study NCT04331080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin® gel 100 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study NCT04331080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granexin® gel 100 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study NCT04331080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin® gel 200 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study NCT04331080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granexin® gel 200 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study NCT04331080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle gel
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study NCT04331080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study NCT00777517 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipitor
Description: A single dose of 10 mg Lipitor tablet
Study NCT00777517 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin pediatric formulation
Description: A single dose of 10 mg atorvastatin pediatric formulation
Study NCT02201602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Study NCT02201602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Study NCT01384539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT01384539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT02192268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEP
Study NCT02192268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFOO
Study NCT02192268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Coughing
Study NCT04574895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hematology Review
Description: VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
Study NCT01446848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron supplement
Description: 325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
Study NCT04111341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM (Gan-Lu-Yin)GLY
Description: TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks